Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daratumumab + Bortezomib + Dexamethasone in Newly Diagnosed Transplant Ineligible Multiple Myeloma
NCT03695744Phase 2Unknown
- Sponsor
- Singapore General Hospital
- Start
- Oct 2019
- Primary completion
- Sep 2021
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of daratumumab in multiple myeloma (MM), sponsored by Singapore General Hospital. Primary endpoint: Overall Response Rate up to 3 years. Status: unknown.
02
Drugs
daratumumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03695744.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03695744.